Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1590/S1413-86702010000800007 | ||||
| Año | 2010 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
The global spread of methicillin-resistant Staphylococcus aureus (MRSA) means it is now a pathogen of worldwide public health concern. Within Latin America, MRSA is highly prevalent, with the proportion of S. aureus isolates that are methicillin-resistant on the rise, yet resources for managing the infection are limited. While several guidelines exist for the treatment of MRSA infections, many are written for the North American or European setting and need adaptation for use in Latin America. In this article, we aim to emphasize the importance of appropriate treatment of MRSA in the healthcare and community settings of Latin America. We present a summary of the available guidelines and antibiotics, and discuss particular considerations for clinicians treating MRSA in Latin America.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Luna, Carlos | Hombre |
UNIV BUENOS AIRES - Argentina
Hospital de Clinicas Jose de San Martin - Argentina Universidad de Buenos Aires - Argentina |
| 2 | Rodriguez-Noriega, E. | Hombre |
Univ Guadalajara - México
Hospital Civil de Guadalajara - México |
| 3 | BAVESTRELLO-FERNANDEZ, LUIS | Hombre |
Clínica Reñaca - Chile
Clin Renaca - Chile |
| 4 | Gotuzzo, E. | Hombre |
UNIV PERUANA CAYETANO HEREDIA - Perú
Universidad Peruana Cayetano Heredia - Perú |
| 5 | Latin Amer Working Grp Gram | Corporación |
| Fuente |
|---|
| Pfizer Inc. |
| Pfizer Inc., New York, NY, USA |
| Pfizer |
| Merck |
| Johnson Johnson |
| Wyeth |
| Cerexa |
| Schering-Plough |
| Sharp Dohme |
| TIBOTEC |